NexaDose Nano Radiation Therapy Patch FDA Approved: Skin Cancer Patients Can Complete Treatment at Home
NexaDose is a flexible patch containing radioactive isotopes that delivers precise low-dose radiation to superficial tumors when applied to the skin surface.
NexaDose Nano Radiation Therapy Patch FDA Approved
On October 1, 2028, the FDA approved NexaDose, a radiation therapy patch developed by Israeli company Nanomedix, for treating superficial basal cell carcinoma and squamous cell carcinoma. This is the world's first radiation therapy device approved for home use.
NexaDose is a 3-centimeter square flexible patch embedded with strontium-90 radiation sources and nano-level dose control layers. Patients apply the patch to the tumor surface, wear it for 4-6 hours, then remove it, repeating weekly for 4-6 weeks to complete treatment. The patch's radiation dose is precisely controlled at tumor depth, minimizing damage to surrounding healthy tissue.
Phase III clinical trials showed NexaDose achieved a 94% complete response rate for superficial basal cell carcinoma, comparable to traditional external beam radiation therapy, but reducing the treatment course from 6-7 weeks to 4 weeks without requiring multiple hospital visits. Nanomedix says the single-treatment cost is approximately $3,000, one-third of traditional radiation therapy.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.